Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in...

ver descrição completa

Detalhes bibliográficos
Autores: Rodríguez-Arévalo, Sergio, Bagan Polonio, Andrea, Griñán Ferré, Christian, Vasilopoulou, Foteini, Pallàs i Llibería, Mercè, 1964-, Brocos-Mosquera, Iria, Callado, Luis F., Loza, María Isabel, Martínez, Antón L., Brea, José, Pérez, Belén, Molins i Grau, Elies, Jonghe, Steven de, Daelemans, Dirk, Radan, Milica, Djikic, Teodora, Nikolic, Katarina, Hernández-Hernández, Elena, García-Fuster, M. Julia, García-Sevilla, Jesús A., Escolano Mirón, Carmen
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/178725
Acesso em linha:https://hdl.handle.net/2445/178725
Access Level:acceso abierto
Palavra-chave:Malaltia d'Alzheimer
Malalties neurodegeneratives
Envelliment
Alzheimer's disease
Neurodegenerative Diseases
Aging
Descrição
Resumo:Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable. Acute treatment in mice with 2-(2-benzofuranyl)-2- imidazole, known as LSL60101 (garsevil), showed non-warning properties in the ADMET studies and an optimal pharmacokinetic profile. Moreover, LSL60101 induced hypothermia in mice while decreased pro-apoptotic FADD protein in the hippocampus. In vivo studies in the familial Alzheimer's disease 5xFAD murine model with the representative compound, revealed significant decreases in the protein expression levels of antioxidant enzymes superoxide dismutase and glutathione peroxidase in hippocampus. Overall, LSL60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress.